Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-549 | PIK-93 | 1 | 72 | 0.32 | 5119.3 | 5328.0 | 1554.9 | -0.495 | 0.956 | 0.961 | 1.777 | BT549 PIK93 0 1 72 |
| BT-549 | PIK-93 | 1 | 72 | 0.1 | 5404.5 | 5328.0 | 1554.9 | -1.0 | 1.020 | 1.010 | 1.777 | BT549 PIK93 0 1 72 |
| BT-20 | PIK-93 | 1 | 72 | 0.32 | 5519.0 | 5875.8 | 1443.3 | -0.495 | 0.939 | 0.939 | 2.025 | BT20 PIK93 0 1 |
| BT-549 | Sirolimus | 1 | 72 | 0.01 | 3561.0 | 5477.5 | 1554.9 | -2.0 | 0.578 | 0.650 | 1.817 | BT549 Rapamycin 0 1 72 |
| BT-20 | CAL-101 | 1 | 72 | 1.0 | 5741.0 | 6240.0 | 1443.3 | 0.0 | 0.923 | 0.920 | 2.112 | BT20 CAL101 0 1 |
| BT-549 | Sirolimus | 1 | 72 | 0.001 | 3655.8 | 5477.5 | 1554.9 | -3.0 | 0.601 | 0.667 | 1.817 | BT549 Rapamycin 0 1 72 |
| BT-20 | PIK-93 | 1 | 72 | 1.0 | 4892.3 | 5875.8 | 1443.3 | 0.0 | 0.827 | 0.833 | 2.025 | BT20 PIK93 0 1 |
| BT-549 | Sirolimus | 1 | 72 | 0.032 | 3539.5 | 5477.5 | 1554.9 | -1.49 | 0.573 | 0.646 | 1.817 | BT549 Rapamycin 0 1 72 |
| BT-549 | Sirolimus | 1 | 72 | 0.32 | 3410.0 | 5477.5 | 1554.9 | -0.495 | 0.541 | 0.623 | 1.817 | BT549 Rapamycin 0 1 72 |
| BT-549 | Sirolimus | 1 | 72 | 0.1 | 3497.0 | 5477.5 | 1554.9 | -1.0 | 0.562 | 0.638 | 1.817 | BT549 Rapamycin 0 1 72 |
| BT-20 | PIK-93 | 1 | 72 | 3.2 | 2878.0 | 5875.8 | 1443.3 | 0.505 | 0.406 | 0.490 | 2.025 | BT20 PIK93 0 1 |
| BT-20 | Dactolisib | 1 | 72 | 3.2 | 900.5 | 5998.3 | 1443.3 | 0.505 | -0.205 | 0.150 | 2.055 | BT20 BEZ235 0 1 |
| BT-20 | CAL-101 | 1 | 72 | 3.2 | 5408.0 | 6240.0 | 1443.3 | 0.505 | 0.869 | 0.867 | 2.112 | BT20 CAL101 0 1 |
| BT-549 | AS605240 | 1 | 72 | 0.01 | 5341.5 | 5429.5 | 1554.9 | -2.0 | 0.982 | 0.984 | 1.804 | BT549 AS605240 0 1 72 |
| BT-20 | Sirolimus | 1 | 72 | 0.001 | 3625.0 | 5856.5 | 1443.3 | -3.0 | 0.577 | 0.619 | 2.021 | BT20 Rapamycin 0 1 |
| BT-20 | AS605240 | 1 | 72 | 3.2 | 5187.0 | 6371.0 | 1443.3 | 0.505 | 0.817 | 0.814 | 2.142 | BT20 AS605240 0 1 |
| BT-20 | AZD-6482 | 1 | 72 | 3.2 | 2032.7 | 5948.8 | 1443.3 | 0.505 | 0.182 | 0.342 | 2.043 | BT20 AZD6482 0 1 |
| BT-549 | AS605240 | 1 | 72 | 0.001 | 5384.8 | 5429.5 | 1554.9 | -3.0 | 0.991 | 0.992 | 1.804 | BT549 AS605240 0 1 72 |
| BT-20 | Sirolimus | 1 | 72 | 0.0032 | 3775.5 | 5856.5 | 1443.3 | -2.49 | 0.609 | 0.645 | 2.021 | BT20 Rapamycin 0 1 |
| BT-20 | AS605240 | 1 | 72 | 0.0032 | 6003.8 | 6371.0 | 1443.3 | -2.49 | 0.945 | 0.942 | 2.142 | BT20 AS605240 0 1 |
| BT-20 | Everolimus | 1 | 72 | 0.001 | 3773.0 | 5781.0 | 1443.3 | -3.0 | 0.616 | 0.653 | 2.002 | BT20 Everolimus 0 1 |
| BT-549 | AS605240 | 1 | 72 | 0.032 | 5197.3 | 5429.5 | 1554.9 | -1.49 | 0.952 | 0.957 | 1.804 | BT549 AS605240 0 1 72 |
| BT-20 | Sirolimus | 1 | 72 | 0.01 | 3763.8 | 5856.5 | 1443.3 | -2.0 | 0.607 | 0.643 | 2.021 | BT20 Rapamycin 0 1 |
| HCC38 | TGX221 | 1 | 72 | 0.1 | 4375.3 | 4281.3 | 1295.5 | -1.0 | 1.030 | 1.020 | 1.724 | HCC38 TGX221 0 1 72 |
| HCC38 | TGX221 | 1 | 72 | 0.032 | 4151.0 | 4281.3 | 1295.5 | -1.49 | 0.964 | 0.970 | 1.724 | HCC38 TGX221 0 1 72 |